Belite Bio (BLTE) Intangibles (2024 - 2025)
Belite Bio (BLTE) posted quarterly Intangibles of $19000.0 for Q4 2025, down 38.71% year-over-year from $31000.0 in Q4 2024, and down 20.83% quarter-over-quarter from $24000.0 in Q3 2025.
Powered by 
Analysis
Belite Bio (BLTE) Intangibles (2024 - 2025) Analysis & Trends
Belite Bio's Intangibles history runs 2 years deep, the most recent figure standing at $19000.0 for Q4 2025.
- In Q4 2025, Intangibles fell 38.71% year-over-year to $19000.0; the TTM figure through Dec 2025 stood at $19000.0 (down 38.71% YoY), while the FY2025 annual figure was $19000.0, down 38.71% from the prior year.
- Intangibles for Q4 2025 stood at $19000.0, down from $24000.0 in the prior quarter.
- The five-year high for Intangibles was $31000.0 in Q4 2024, with the low at $19000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 266.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 63.28 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 60.96 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Belite Bio | 6.44 Bn | 6.44 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 19,000.00 |
| Sep 30, 2025 | 24,000.00 |
| Dec 31, 2024 | 31,000.00 |